Efficacy and Safety of HD-6277, a Novel G ProteinCoupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial.

Saved in:

Bibliographic Details
Title:	Efficacy and Safety of HD-6277, a Novel G ProteinCoupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial.
Authors:	Lee, Yong-ho^1,2,3, Min, Kyung Wan⁴, Hong, Jun Hwa⁵, Lim, Soo⁶, Yu, Jae Myung⁷, Chung, Choon Hee⁸, Moon, Jun Sung⁹, Won, Jong Chul¹⁰, Ahn, Chul Woo¹¹, Lee, Jie-Eun¹², Kim, Tae Nyun¹³, Lee, Byung-Wan^1,2 bwanlee@yuhs.ac
Source:	Diabetes & Metabolism Journal. May2026, Vol. 50 Issue 3, Following p576-586. 20p.
Database:	Academic Search Ultimate

Description
ISSN:	22336079
DOI:	10.4093/dmj.2025.0528